EP2704694A4 - Rapid dissolve tablet compositions for vaginal administration - Google Patents

Rapid dissolve tablet compositions for vaginal administration

Info

Publication number
EP2704694A4
EP2704694A4 EP12779335.4A EP12779335A EP2704694A4 EP 2704694 A4 EP2704694 A4 EP 2704694A4 EP 12779335 A EP12779335 A EP 12779335A EP 2704694 A4 EP2704694 A4 EP 2704694A4
Authority
EP
European Patent Office
Prior art keywords
vaginal administration
tablet compositions
rapid dissolve
dissolve tablet
rapid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12779335.4A
Other languages
German (de)
French (fr)
Other versions
EP2704694A1 (en
Inventor
Gopi Venkatesh
Vijaya Swaminathan
Jin-Wang Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of EP2704694A1 publication Critical patent/EP2704694A1/en
Publication of EP2704694A4 publication Critical patent/EP2704694A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
EP12779335.4A 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration Withdrawn EP2704694A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481582P 2011-05-02 2011-05-02
PCT/US2012/036055 WO2012151237A1 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration

Publications (2)

Publication Number Publication Date
EP2704694A1 EP2704694A1 (en) 2014-03-12
EP2704694A4 true EP2704694A4 (en) 2014-11-19

Family

ID=47108022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12779335.4A Withdrawn EP2704694A4 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration

Country Status (16)

Country Link
EP (1) EP2704694A4 (en)
JP (1) JP6154803B2 (en)
KR (2) KR20140014264A (en)
CN (1) CN103596556A (en)
AP (1) AP2013007268A0 (en)
AR (1) AR086249A1 (en)
AU (1) AU2012250862B2 (en)
CA (1) CA2839790A1 (en)
CL (1) CL2013003161A1 (en)
CO (1) CO6940408A2 (en)
IL (1) IL229170A0 (en)
MX (1) MX2013012745A (en)
RU (1) RU2013150323A (en)
SG (1) SG194725A1 (en)
TW (1) TW201247240A (en)
WO (1) WO2012151237A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352907B2 (en) 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド Compositions and methods for enhancing the effectiveness of contraceptive fungicides
CA2906642A1 (en) * 2013-03-15 2014-09-18 Conrad Low-glycerin formulations for hiv treatment and prevention
WO2015070072A1 (en) * 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
RU2691950C1 (en) * 2013-12-19 2019-06-19 Ивофем, Инк. Compositions and methods for inhibiting inflammation and diseases using alginic acid-based antimicrobial compound
CN110179801B (en) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 Posaconazole medicine composition, preparation method and medicine preparation thereof
AU2015302059B2 (en) 2014-08-12 2020-02-06 Nextgen Jane, Inc. System and method for monitoring health based on collected bodily fluid
CN104434992B (en) * 2014-12-21 2018-06-08 昆明赛诺制药股份有限公司 A kind of American-cockroach-extract bioadhesive vaginal tablets and preparation method thereof
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
EP3442706B1 (en) 2016-04-13 2025-07-23 NextGen Jane, Inc. Sample collection and preservation methods
EP3522879A4 (en) 2016-10-04 2020-06-03 Evofem, Inc. METHOD FOR TREATING AND PREVENTING BACTERIAL VAGINOSIS
CA3040422A1 (en) * 2016-10-13 2018-04-19 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
WO2019068862A1 (en) 2017-10-06 2019-04-11 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
AU2019365204B2 (en) * 2018-10-23 2025-08-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations
MX2021007525A (en) * 2018-12-21 2021-09-21 Univ Liverpool Nrti therapies.
WO2020213983A1 (en) * 2019-04-19 2020-10-22 한양대학교 산학협력단 Thermosensitive composition containing phosphatidic acid and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082596A2 (en) * 2005-01-19 2006-08-10 Kamalinder Kaur Singh Neem oil contraceptive formulations
WO2010048389A2 (en) * 2008-10-23 2010-04-29 Henkel Corporation Pharmaceutical pellets comprising modified starch and therapeutic applications therefor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20040228932A1 (en) * 2003-05-12 2004-11-18 Pilgaonkar Pratibha S. Pharmaceutical excipient
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
JP2006022039A (en) * 2004-07-08 2006-01-26 Towa Yakuhin Kk Simvastatin solid preparation having high stability
UA93354C2 (en) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
CN1257715C (en) * 2004-08-02 2006-05-31 程月发 Clindamycin metronidazole vagina effervescent tablet and its preparing method and use
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
CN1970079A (en) * 2006-12-08 2007-05-30 陕西沃普森制药有限公司 Vagina effervescence tablet of recombinant human interferon alpha-2a and preparation process thereof
EP2656879B1 (en) * 2006-12-10 2017-06-28 Chongxi Yu Transdermal delivery systems of beta-lactam antibiotics
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
BRPI0821761A2 (en) * 2007-12-21 2015-06-16 Eurand Inc Temazepam Oral Disintegrating Tablet Compositions
CN101283989A (en) * 2008-02-28 2008-10-15 何文健 Metronidazole vaginal tablet process and quality control method
CN101406463B (en) * 2008-02-28 2012-04-25 陕西君碧莎制药有限公司 Metronidazole, clotrimazole and chlorhexidine acetate vaginal effervescent tablet and preparation method thereof
CN101780203B (en) * 2010-03-16 2012-09-05 刘仁杰 Lubrication effervescent agent for yin nourishing, nest warming, body deodorizing and youth keeping and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082596A2 (en) * 2005-01-19 2006-08-10 Kamalinder Kaur Singh Neem oil contraceptive formulations
WO2010048389A2 (en) * 2008-10-23 2010-04-29 Henkel Corporation Pharmaceutical pellets comprising modified starch and therapeutic applications therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POELVOORDE N ET AL: "In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 73, no. 2, 1 October 2009 (2009-10-01), pages 280 - 284, XP026652689, ISSN: 0939-6411, [retrieved on 20090612], DOI: 10.1016/J.EJPB.2009.06.005 *
See also references of WO2012151237A1 *

Also Published As

Publication number Publication date
KR20160112012A (en) 2016-09-27
AU2012250862B2 (en) 2015-07-09
MX2013012745A (en) 2014-12-05
IL229170A0 (en) 2013-12-31
NZ617376A (en) 2016-03-31
JP6154803B2 (en) 2017-06-28
TW201247240A (en) 2012-12-01
AU2012250862A1 (en) 2013-05-02
CN103596556A (en) 2014-02-19
CA2839790A1 (en) 2012-11-08
RU2013150323A (en) 2015-06-10
CO6940408A2 (en) 2014-05-09
SG194725A1 (en) 2013-12-30
WO2012151237A1 (en) 2012-11-08
JP2014513124A (en) 2014-05-29
AR086249A1 (en) 2013-11-27
EP2704694A1 (en) 2014-03-12
KR20140014264A (en) 2014-02-05
CL2013003161A1 (en) 2014-08-01
AP2013007268A0 (en) 2013-11-30

Similar Documents

Publication Publication Date Title
IL229170A0 (en) Rapid dissolve tablet compositions for vaginal administration
AP3864A (en) Pharmaceutical composition
EP2629786A4 (en) Compositions for drug administration
IL230861A (en) Fast dissolving pharmaceutical composition
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
IL222087A (en) Fast dissolving pharmaceutical composition
GB201118232D0 (en) Pharmaceutical composition
LT2672973T (en) Administration regime for nitrocatechols
IL232305A0 (en) Pharmaceutical formulations
IL222086A (en) Fast dissolving pharmaceutical composition
GB2525835B (en) Pharmaceutical agent
ZA201308157B (en) Pharmaceutical composition
EP2727593A4 (en) Nicorandil-containing pharmaceutical composition
GB201118181D0 (en) Pharmaceutical compositions
PL2709599T3 (en) Pharmaceutical composition comprising drotaverine
EP2711010A4 (en) Pharmaceutical composition
HRP20141173T1 (en) Pharmaceutical comprising myramistin
HUP1100444A2 (en) Pharmaceutical composition
IL228742A0 (en) Solid pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
GB201108234D0 (en) Pharmaceutical agent
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
GB201111577D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141020

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/513 20060101ALI20141014BHEP

Ipc: A61K 9/16 20060101AFI20141014BHEP

Ipc: A61K 9/20 20060101ALI20141014BHEP

Ipc: A61K 31/675 20060101ALI20141014BHEP

Ipc: A61P 31/18 20060101ALI20141014BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADARE PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170303

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180719

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SWAMINATHAN, VIJAYA

Inventor name: LAI, JIN-WANG

Inventor name: VENKATESH, GOPI

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20181218

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190430